SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma Advanced Research’s net loss narrows to Rs 56.72 crore in Q4

18 May 2021 Evaluate

Sun Pharma Advanced Research Company has reported results for fourth quarter and year ended March 31, 2021.

The company has reported net loss at Rs 56.72 crore for the quarter under review as compared to net loss of Rs 99.54 crore for the same quarter in the previous year. Total income of the company increased by 9.91% at Rs 28.39 crore for Q4FY21 as compared Rs 25.83 crore for the corresponding quarter previous year.

For the year ended March 31, 2021, the company has reported net loss at Rs 151.14 crore as compared to net loss of Rs 312.40 crore for the previous year. Total income of the company reported above 2- fold jump at Rs 258.37 crore for year under review as compared to Rs 86.58 crore for year ended March 31, 2020.

Sun Pharma Adv. Res Share Price

147.90 -4.25 (-2.79%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 435.70
Indegene 486.80
CMS Info Systems 318.00
JITF Infralogistics 338.00
Sagility 42.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×